- recruitingPHASE2
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
This study looks at how two medicines, Bosentan and dapagliflozin, might help people with a condition called Large Vessel Vasculitis (LVV). LVV damages blood vessels, increasing risks like heart attacks. We want to see if these medicines can improve blood vessel health.
United Kingdom - active not recruiting
PET Imaging of Giant Cell and Takayasu Arteritis
This study is looking for better ways to spot and track types of blood vessel inflammation called Giant Cell Arteritis and Takayasu Arteritis. We're using new scanning methods called PET-MRI to see if they can show inflammation more clearly than current tests, especially after treatment.
United Kingdom - recruiting
Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
This study wants to learn about Takayasu arteritis from both patients and doctors. It uses two online questionnaires to understand experiences, treatments, and challenges, helping improve care for this rare condition in the UK.
United Kingdom - not yet recruitingNA
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
This study aims to improve how we diagnose and monitor a condition called Large Vessel Vasculitis (LVV) using a new type of body scan. The goal is to make these scans clearer, faster, and potentially lead to better, more personalised treatment plans for patients with LVV.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
This study, called STARS, is looking at a new medicine for Takayasu arteritis, a condition that makes blood vessels inflamed. Researchers want to see if this medicine, called secukinumab (Cosentyx), works better and is safer than usual treatments for severe forms of the disease.
France